[HTML][HTML] COVID-19: a case for inhibiting IL-17?
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - Nature Reviews Immunology, 2020 - go.gale.com
The number of cases and deaths due to coronavirus disease 2019 (COVID-19) are
staggering. Currently, there is no specific treatment available for this disease and off-label …
staggering. Currently, there is no specific treatment available for this disease and off-label …
COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - Nature reviews. Immunology, 2020 - europepmc.org
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
[PDF][PDF] COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - academia.edu
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
[引用][C] COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - Nature Reviews Immunology, 2020 - cir.nii.ac.jp
[HTML][HTML] COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - Nature Reviews. Immunology, 2020 - ncbi.nlm.nih.gov
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman… - Nature reviews …, 2020 - pubmed.ncbi.nlm.nih.gov
IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
[引用][C] COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman… - Nature Reviews …, 2020 - mdanderson.elsevierpure.com
COVID-19: a case for inhibiting IL-17? — MD Anderson Cancer Center Skip to main navigation
Skip to search Skip to main content MD Anderson Cancer Center Home MD Anderson Cancer …
Skip to search Skip to main content MD Anderson Cancer Center Home MD Anderson Cancer …
COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - 2020 - cabidigitallibrary.org
Abstract IL-17 and IL-17 receptor inhibitors boast an impressive safety history and are widely
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
available. Here, we argue that targeting IL-17 is immunologically plausible as a strategy to …
[HTML][HTML] COVID-19: a case for inhibiting IL-17?
O Pacha, MA Sallman, SE Evans - Nature reviews. Immunology, 2020 - ncbi.nlm.nih.gov
IL-17 inhibition boasts an impressive safety history, is immunologically plausible as a
strategy to prevent ARDS in COVID-19, and is widely available. Here we discuss why we …
strategy to prevent ARDS in COVID-19, and is widely available. Here we discuss why we …